HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Peters, J. I. Articles by LeGrand, T. S. Search for Related Content PubMed PubMed Citation Articles by Peters, J. I. Articles by LeGrand, T. S.

A Randomized, Placebo-Controlled Study To Evaluate the Role of Salmeterol in the In-Hospital Management of Asthma^*

^* From the Department of Medicine (Dr. Peters), Division of Pulmonary Diseases/Critical Care Medicine, The Department of Respiratory Care (Drs. Shelledy, Jones, and LeGrand, and Mr. Lawson), and The Department of Surgery (Dr. Davis), The University of Texas Health Science Center at San Antonio, TX.

Correspondence to: Jay I. Peters, MD, FCCP, Pulmonary Disease Section (111E), South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division, 7400 Merton Minter Blvd, San Antonio, TX 78284; e-mail: peters{at}uthscsa.edu

Study objectives: To assess the safety and efficacy of salmeterol xinafoate as an adjunct to conventional therapy for the in-hospital management of acute asthma.

Design: A prospective, double-blind, randomized placebo-controlled trial.

Setting: Medical wards of a large university-based hospital.

Patients: Forty-three patients admitted for an acute exacerbation of asthma.

Interventions: Salmeterol (42 µg) or two puffs of placebo every 12 h in addition to standard therapy (short-acting ß-agonists, corticosteroids, and anticholinergic agents).

Results: No clinically adverse effects were seen with the addition of salmeterol to conventional therapy. After salmeterol, there was no difference in pulse, respiratory rate, oxygen saturation by pulse oximetry, severity of symptoms, or dyspnea score. Patients receiving salmeterol had greater FEV₁ percent improvements than the placebo group at 12, 24, 36, and 48 h. These findings were not statistically significant. By paired Student’s t tests, there were significant improvements in FEV₁ (p = 0.03) and FVC (p = 0.03) in the salmeterol group after 48 h of treatment with no comparable improvement in the placebo group. In a subgroup analysis of patients with an initial FEV₁ 1.5 L, the absolute FEV₁ percent improvement for salmeterol vs placebo was 51% vs 16% at 24 h and 54% vs 40% at 48 h. The relative FEV₁ percent improvement for salmeterol vs placebo was 17% vs 8% at 24 h and 18% vs 14% at 48 h.

Conclusion: The addition of salmeterol to conventional therapy is safe and may benefit hospitalized patients with asthma. Further studies are needed to clarify its role in the treatment of acute exacerbation of asthma.

Key Words: asthma • ß-agonists • salmeterol

This article has been cited by other articles:

				R. Buhl and S. G. Farmer Current and Future Pharmacologic Therapy of Exacerbations in Chronic Obstructive Pulmonary Disease and Asthma Proceedings of the ATS, April 1, 2004; 1(2): 136 - 142. [Abstract] [Full Text] [PDF]

				B. J. Lipworth, J. I. Peters, and D. Shelledy Salmeterol and Conventional Asthma Therapy Chest, March 1, 2001; 119(3): 986 - 987. [Full Text] [PDF]